PIONeeR Project Set to Reveal Groundbreaking Lung Cancer Findings
The upcoming ESMO Congress is gearing up to showcase a pivotal moment in cancer research as the PIONeeR Project presents late-breaking findings from its innovative Phase Ib/IIa umbrella study. This noteworthy presentation, taking place during the Presidential Symposium called "Eyes to the Future," represents a vital advancement in understanding how to overcome resistance among patients with advanced non-small cell lung cancer (NSCLC) who are using PD-(L)1 immune checkpoint inhibitors.
Overview of the PIONeeR Project
The PIONeeR Project stands for Precision Immuno-Oncology for advanced Non-Small Cell Lung Cancer Patients with PD-(L)1 ICI Resistance. This ambitious international initiative unites a network of research hospitals and universities. Spearheaded by Pr Pascale Tomasini as the principal investigator, the project has brought together the expertise of over 100 scientists collaborating across a range of countries.
Innovative Approach to Cancer Treatment
The design of this trial introduces a significant shift in how clinical trials are conducted. By employing an adaptive model that allows for real-time decision-making, the PIONeeR Project aims to identify potential signals of efficacy through new combinations of immune checkpoint inhibitors. This adaptive strategy is especially important given the pressing challenges posed by resistance mechanisms in patients with advanced NSCLC, particularly those whose current treatments have been ineffective.
Highlights from the Upcoming Announcement
At the ESMO Congress, participants can anticipate a thorough presentation that will unveil initial results from the clinical trial. Prof. Fabrice Barlesi, a leading voice in the progress of this project, shared his enthusiasm for the collective efforts and commitment shown by the patients involved. More than 450 patients have contributed to the study's biomarker component, which aims to deepen our understanding of treatment responses and resistance patterns, ultimately paving the way for better therapeutic strategies for lung cancer.
Details of the Presentation
- Title: Precision Immuno-Oncology for advanced Non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors Resistance (PIONeeR): a phase Ib/IIa clinical trial targeting identified resistance pathways.
- Presentation Number: LBA8.
- Presenter: Pr Pascale Tomasini, Aix Marseille Université, AP-HM, Early Phase Clinical Trials in Oncology Unit.
- Presentation Time: Scheduled for Monday, from 4:30 - 6:15 pm CEST.
Attendees will have the opportunity to access the abstract on the ESMO website, and all accepted abstracts will later appear in the official ESMO journal, Annals of Oncology.
About the Research and Collaborators
The PIONeeR Project is recognized for its impactful contributions to cancer research, positioning itself as a leader in the battle against lung cancer. Funded through the Investments for the Future program and backed by various research institutions and hospitals, this project embodies the teamwork necessary to confront one of the most urgent challenges in oncology today. The diverse partnership includes prominent contributors such as Marseille Immunopôle, Aix Marseille Université, Inserm, CNRS, and several distinguished hospitals.
Contact Information
If you have any questions regarding the PIONeeR Project, feel free to reach out to Marie Puvieux at ATCG Partners via communication@the-pioneer-project.org.
Frequently Asked Questions
What is the PIONeeR Project?
The PIONeeR Project is a significant international research effort aimed at overcoming resistance to PD-(L)1 immune checkpoint inhibitors in patients with advanced NSCLC.
Who will present the findings at ESMO Congress?
Pr Pascale Tomasini will be the one presenting the findings from the PIONeeR Project at the congress.
When is the presentation scheduled?
The presentation is planned for Monday, from 4:30 - 6:15 pm CEST.
What role have patients played in this study?
Over 450 patients have been involved in the biomarker program, making substantial contributions that advance the research and understanding of resistance in lung cancer therapies.
Where can I find more information about the abstract?
The abstract will be available on the ESMO website following the presentation, and it will also be published in the official ESMO journal.
